Ling W, Nadipelli VR, Solem CT, Farabee D, Ronquest NA, Perrochet B, Learned SM, Deshpande CG, Heidbreder C. Measuring recovery in opioid use disorder: clinical utility and psychometric properties of the Treatment Effectiveness Assessment. Subst Abuse Rehabil. 2019 Jun 5;10:13-21. doi: 10.2147/SAR.S198361
Ronquest NA, Willson TM, Montejano LB, Nadipelli VR, Wollschlaeger BA. Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder. Subst Abuse Rehabil. 2018 Sep 21;9:59-78. doi: 10.2147/SAR.S150253
Boscarino JA, Kirchner HL, Pitcavage JM, Nadipelli VR, Ronquest NA, Fitzpatrick MH, Han JJ. Factors associated with opioid overdose: a 10-year retrospective study of patients in a large integrated health care system. Subst Abuse Rehabil. 2016 Sep 16;7:131-41. doi: 10.2147/SAR.S108302
Ward MA, Fang G, Richards KL, Walko CM, Earnshaw SR, Happe LE, Blalock S. Treatment interruption and regimen change in first-generation vs. second-generation tyrosine kinase inhibitors used as first-line therapy for chronic myeloid leukemia. JHEOR. 2015 Apr;2(2):181-91.
Davis KL, Gutierrez B, Zyczynski T, Kaye JA. Real-world treatment patterns in men with castration-resistant prostate cancer receiving docetaxel. JHEOR. 2015 Jan 6;2(2):119-30. doi: 10.36469/9894